# US 2021/0060170 A1 · Photodynamic therapy composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0060170 A1
- Document ID: US20210060170A1
- Status: Published application
- Kind: A1
- Application number: 16/901,874
- Filed: 2020-06-15
- Published: 2021-03-04
- Earliest claimed: 2013-02-15
- Assignees: Case Western Reserve University
- Applicants: Case Western Reserve University
- Inventors: James Basilion
- Web page: https://patentgrep.com/patent/US20210060170A1

## CPC

- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 31/695: Silicon compounds
- A61K 41/0071: {PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines}
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61K 47/645: {Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT}
- A61K 49/0036: {Porphyrins (used in photodynamic therapy A61K41/0071 or A61K41/0076; used as targeting group or modifying agent for targeting a therapeutic compound A61K47/546)}
- A61K 49/0052: {Small organic molecules (oligomers, polymers, dendrimers A61K49/0054)}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A method of treating a PSMA expressing cancer in a subject includes (a) administering to the subject a PSMA-targeted phthalocyanine conjugate compound having the formula (I), (b) detecting the PSMA-targeted phthalocyanine compound bound to and/or complexed with the prostate cancer cells to determine the location and/or distribution of the prostate cancer cells in the subject, (c) surgical resection of the detected cancer, and (d) irradiating the PSMA-targeted phthalocyanine compound at the site of surgical resection, thereby inducing the cytotoxic effects of the phthalocyanine compound on residual prostate cancer cells following surgical resection.

## Claims

### Claim 1

A method for treating a PSMA expressing cancer comprising:
(a) administering systemically to a subject with PSMA expressing cancer a therapeutically effective amount of a pharmaceutical composition, the pharmaceutical composition comprising a PSMA-targeted phthalocyanine compound having the formula (I):
wherein X is a PSMA targeting moiety;
R1, R4, R5, R8, R9, R12, R13, and R16 are each independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, and methyl;
R2, R3, R6, R7, R10, R11, R14, and R15 are each independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, carboxy, aryl, heteroaryl, carbocyclyl, heterocyclyl, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, C1-6 alkoxy, C1-6 acyl, C1-6 alkylcarbonyloxy, C1-6 carbocyclylalkyl, C1-6 aminoalkyl, C1-6 alkylamino, C1-6 thioalkyl, C1-6alkylthio, C1-6hydroxyalkyl, C1-6 alkyloxycarbonyl, C1-6 alkylaminocarbonyl, and C1-6 alkylcarbonylamino; and pharmaceutically acceptable salts thereof;
(b) detecting the PSMA-targeted phthalocyanine compound bound to and/or complexed with the cancer cells to determine the location and/or distribution of the cancer cells in the subject;
(c) surgically resecting the cancer in the subject, wherein the detected PSMA-targeted phthalocyanine compound bound to and/or complexed with the cancer cells guide surgical resection of the cancer; and
(c) irradiating the PSMA-targeted phthalocyanine compound in the site of surgical resection, thereby inducing the cytotoxic effects of the phthalocyanine compound on residual cancer cells following surgical resection.

### Claim 2 (depends on 1)

The method of claim 1, wherein R1-R16 of the phthalocyanine compound are independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, and methyl.

### Claim 3 (depends on 1)

The method of claim 1, the PSMA targeting moiety is a PSMA-1 ligand comprising a PSMA-1 ligand.

### Claim 4 (depends on 1)

The method of claim 1, wherein intra-operative imaging (IOI) of the PSMA-targeted phthalocyanine compound bound to and/or complexed with the cancer cells defines a tumor margin in the subject to guide surgical resection of the cancer.

### Claim 5 (depends on 1)

The method of claim 1, the phthalocyanine compound having the formula (II):
wherein X is a PSMA targeting moiety;
R1, R4, R5, R8, R9, R12, R13, and R16 are each independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, and methyl;
R2, R3, R6, R7, R10, R11, R14, and R15 are each independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, carboxy, aryl, heteroaryl, carbocyclyl, heterocyclyl, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, C1-6 alkoxy, C1-6 acyl, C1-6 alkylcarbonyloxy, C1-6 carbocyclylalkyl, C1-6 aminoalkyl, C1-6 alkylamino, C1-6 thioalkyl, C1-6alkylthio, C1-6hydroxyalkyl, C1-6 alkyloxycarbonyl, C1-6 alkylaminocarbonyl, and C1-6 alkylcarbonylamino; and pharmaceutically acceptable salts thereof.

### Claim 6 (depends on 5)

The method of claim 5, wherein R1-R16 of the phthalocyanine compound are independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, and methyl.

### Claim 7 (depends on 1)

The method of claim 1, the phthalocyanine compound having the formula (III):
wherein X is a PSMA targeting moiety;
R1, R4, R5, R8, R9, R12, R13, and R16 are each independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, and methyl;
R2, R3, R6, R7, R10, R11, R14, and R15 are each independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, carboxy, aryl, heteroaryl, carbocyclyl, heterocyclyl, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, C1-6 alkoxy, C1-6 acyl, C1-6 alkylcarbonyloxy, C1-6 carbocyclylalkyl, C1-6 aminoalkyl, C1-6 alkylamino, C1-6 thioalkyl, C1-6alkylthio, C1-6hydroxyalkyl, C1-6 alkyloxycarbonyl, C1-6 alkylaminocarbonyl, and C1-6 alkylcarbonylamino; and pharmaceutically acceptable salts thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein R1-R16 of the phthalocyanine compound are independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, and methyl.

### Claim 9 (depends on 1)

The method of claim 1, the phthalocyanine compound having the formula (IV):
wherein X is a PSMA-1 ligand; and pharmaceutically acceptable salts thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein the PSMA targeted phthalocyanine compound is administered by intravenous injection.

### Claim 11 (depends on 1)

The method of claim 1, wherein the PSMA targeted phthalocyanine compound is formulated in a pharmaceutically acceptable carrier.

### Claim 12 (depends on 1)

The method of claim 1, wherein the PSMA expressing cancer is selected from the group consisting of renal carcinoma, transitional cell carcinoma of the urinary bladder, testicular embryonal carcinoma, colonic adenocarcinoma, neuroendocrine carcinoma, gliobastoma multiforme, malignant melanoma, pancreatic ductal carcinoma, non-small cell lung carcinoma, soft tissue carcinoma, breast carcinoma, and prostatic adenocarcinoma.

### Claim 13 (depends on 12)

The method of claim 12, wherein the cancer is metastatic prostate cancer.

### Claim 14 (depends on 1)

The method of claim 1, wherein the surgical resection site is irradiated with an amount of radiation effective to inhibit tumor recurrence in the subject.

### Claim 15

A method for treating a prostate cancer comprising:
(a) administering systemically to a subject with prostate cancer a therapeutically effective amount of a PSMA targeted phthalocyanine compound, the pharmaceutical composition comprising a phthalocyanine compound having the formula (I):
wherein X is a PSMA targeting moiety;
R1, R4, R5, R8, R9, R12, R13, and R16 are each independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, and methyl;
R2, R3, R6, R7, R10, R11, R14, and R15 are each independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, carboxy, aryl, heteroaryl, carbocyclyl, heterocyclyl, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, C1-6 alkoxy, C1-6 acyl, C1-6 alkylcarbonyloxy, C1-6 carbocyclylalkyl, C1-6 aminoalkyl, C1-6 alkylamino, C1-6 thioalkyl, C1-6alkylthio, C1-6hydroxyalkyl, C1-6 alkyloxycarbonyl, C1-6 alkylaminocarbonyl, and C1-6 alkylcarbonylamino; and pharmaceutically acceptable salts thereof;
(b) detecting the PSMA-targeted phthalocyanine compound bound to and/or complexed with the prostate cancer cells to determine the location and/or distribution of the prostate cancer cells in the subject;
(c) surgically resecting the prostate cancer in the subject, wherein the detected PSMA-targeted phthalocyanine compound bound to and/or complexed with the prostate cancer cells guide surgical resection of the prostate cancer; and
(c) irradiating the PSMA-targeted phthalocyanine compound at the site of surgical resection, thereby inducing the cytotoxic effects of the phthalocyanine compound on residual prostate cancer cells following surgical resection.

### Claim 16 (depends on 15)

The method of claim 15, wherein R1-R16 of the phthalocyanine compound are independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, and methyl.

### Claim 17 (depends on 15)

The method of claim 15, the PSMA targeting moiety comprising a PSMA-1 ligand.

### Claim 18 (depends on 15)

The method of claim 15, wherein intra-operative imaging (IOI) of the PSMA-targeted phthalocyanine compound bound to and/or complexed with the cancer cells defines a tumor margin in the subject to guide surgical resection of the cancer.

### Claim 19 (depends on 15)

The method of claim 15, the phthalocyanine compound having the formula (II):
wherein X is a PSMA targeting moiety;
R1, R4, R5, R8, R9, R12, R13, and R16 are each independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, and methyl;
R2, R3, R6, R7, R10, R11, R14, and R15 are each independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, carboxy, aryl, heteroaryl, carbocyclyl, heterocyclyl, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, C1-6 alkoxy, C1-6 acyl, C1-6 alkylcarbonyloxy, C1-6 carbocyclylalkyl, C1-6 aminoalkyl, C1-6 alkylamino, C1-6 thioalkyl, C1-6alkylthio, C1-6hydroxyalkyl, C1-6 alkyloxycarbonyl, C1-6 alkylaminocarbonyl, and C1-6 alkylcarbonylamino; and pharmaceutically acceptable salts thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein R1-R16 of the phthalocyanine compound are independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, and methyl.

### Claim 21 (depends on 15)

The method of claim 15, the phthalocyanine compound having the formula (III):
wherein X is a PSMA targeting moiety;
R1, R4, R5, R8, R9, R12, R13, and R16 are each independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, and methyl;
R2, R3, R6, R7, R10, R11, R14, and R15 are each independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, carboxy, aryl, heteroaryl, carbocyclyl, heterocyclyl, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, C1-6 alkoxy, C1-6 acyl, C1-6 alkylcarbonyloxy, C1-6 carbocyclylalkyl, C1-6 aminoalkyl, C1-6 alkylamino, C1-6 thioalkyl, C1-6alkylthio, C1-6hydroxyalkyl, C1-6 alkyloxycarbonyl, C1-6 alkylaminocarbonyl, and C1-6 alkylcarbonylamino; and pharmaceutically acceptable salts thereof.

### Claim 22 (depends on 21)

The method of claim 21, wherein R1-R16 of the phthalocyanine compound are independently selected from the group consisting of hydrogen, halogen, nitro, cyano, hydroxyl, thiol, amino, and methyl.

### Claim 23 (depends on 15)

The method of claim 15, the phthalocyanine compound having the formula (IV):
wherein X is a PSMA-1 ligand; and pharmaceutically acceptable salts thereof.

### Claim 24 (depends on 15)

The method of claim 15, wherein the PSMA targeted phthalocyanine compound is administered by intravenous injection.

### Claim 25 (depends on 15)

The method of claim 15, wherein the PSMA targeted phthalocyanine compound is formulated in a pharmaceutically acceptable carrier.

### Claim 26 (depends on 15)

The method of claim 15, wherein the cancer is PSMA expressing metastatic prostate cancer.

### Claim 27 (depends on 15)

The method of claim 15, wherein the surgical resection site is irradiated with an amount of radiation effective to inhibit tumor recurrence in the subject.
